Site logo

Pooled analysis shows finerenone reduces all-cause mortality but not cardiovascular death

By September 2, 2024 Osteopathy

A pooled analysis of three large trials failed to demonstrate significant reductions in cardiovascular death with finerenone, but significantly lower all-cause mortality, cardiovascular events and kidney outcomes were observed, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.

Sign in

Sign Up

Forgot Password

Cart

Basket

Share